1. Dried Blood Spot Collection Device
Touch Spot
Dried Blood Spot Collection Device
Collaboration between Simplexity Product Development and Oregon Health & Science University
Confidential. All Rights Reserved

2. Executive Overview Touch Spot
Touch Spot is a simple device to collect a small, accurate volume of blood with precision from a single finger/heel prick.
Can be easily used by patients of all ages and still works even if the skin touches the device.
Chronic diseases require repeated blood tests (most often using venipuncture) to monitor success of therapeutic interventions.
Current
Proposed
Repeated Venipuncture draws:
Technically difficult
Painful
Traumatizing
Expensive
Interfere with daily activities
Touch Spot

3. Unmet Need – A Better Way to Collect Blood
People need a way to collect blood for therapeutic monitoring other than venipuncture.
Dried blood spot (DBS) testing common in newborns since the 1970s and is similar to at-home glucose monitoring.
Over 800,000 clinical visits per year eliminated using DBS testing in solid organ transplants in the USA alone. Number is dwarfed by total blood collection market.
Affordable Care Act mandates changes: low cost monitoring of patients to prevent hospitalizations and improve outcomes (lowering medical costs).
Other DBS devices exist but are suited for use in the lab, not home use.
Other uses:
Cancer
Infectious diseases such as:
HIV/Aids
Ebola
Chronic diseases such as:
Epilepsy
Cystic Fibrosis
Drug rehabilitation
Epidemiological purposes
Research
Remote Testing
Developing Countries
Veterinary medicine
Barrier to entry is therefore low
Affordable Care Act – This is a worldwide concern
Red portion – Could it read, “dried blood spot (DBS) testing in newborns and at-home glucose monitoring common since the 1970s”???
Potential market far exceeds current target segment of solid organ transplants
Touch Spot

4. Comparison to the Competition
1. DMPK paper cards
2. Phenomenex Mitra
3. Spot On Science Hemaspot
4. Touch Spot 4 3 2 1
Device
Precise blood volume
Amount of blood needed
Quantitative results
Prevents touch failures
Home use
Lab use 1
DMPK cards
Only after punch
A few drops No
Yes 2
Mitra 3
Hemaspot
Many drops 4
Touch Spot
Less than one drop
Touch Spot

5. Disruptive Device – The Science
Why Disruptive?
Collect an accurate and precise sample at home or on the go
Send to lab via regular air mail for mass spectrometry analysis
Determines the blood/drug levels independent of the hematocrit
Permits small sample collection made possible by sensitive LC-MS/MS
Eliminates touch failures associated with traditional method – 50%
Touch Spot: Key to collecting accurate and precise volume and eliminating touch failures.
Current DBS Card – Poor spots
Touch Spot

6. The Team is in Place, and Well Rounded
Dr. Amira Al-Uzri
Pediatric Transplant
Physician
OHSU
Dr. Dennis Koop
Pharmacokinetics
Lab Director
OHSU
Dorota Shortell, MSME
President,
Simplexity Product
Development
Andrew Chitty, MBA
Program Manager
OHSU Cores
Ethan Vella
Senior Mech Engr.
Simplexity
Trina Voss
OHSU
Tech Transfer
Jonathan Jubera
OCTRI
Project Manager
Colleen Lay
OCTRI
Program Director
Transplant Doctor
Phamacokinetics Laboratory
Fluidics Engineering & New Product Development
Laboratory Products Business
Legal, Contracts
Touch Spot

7. Milestones, Momentum/Traction
Stage 1
Proof of concept
Assays tested
Summer 2012
Stage 2
First three Prototypes
Successful testing, redesign
Stage 3
Build, Test, evaluate, refine
Multiple iterations
Stage 4
Preproduction, FDA Approval
Marketing, Distribution
Stage 5
Production
Product Launch
WE ARE HERE
TECHNOLOGY/IP
The IP is co-owned by OHSU and Simplexity (agreement already in place)
Provisional Patent application 62/037,068 was filed 8/13/14.
Utility patent application will be filed in Aug. 2015
Successful interdisciplinary partnership for three years
Technology to analyze accurate and precise DBS in place - LC-MS/MS
Successful early prototypes
Transplant market first of a large dried blood spot collection market
Market opening now
Touch Spot

8. Looking For
Funding: $250,000 to $500,000 for development and testing
Open to a variety of options that advances the device to a market-ready stage
Grants
Partnerships
Philanthropy
SBIR/STTR
Investment capital
Goal: Be the first to market with a comprehensive marketing/distribution plan and a design that meets the needs of targeted populations such as transplant patients.
Options considered:
Create a new Start Up to commercialize technology
Licensing agreement with established medical device organization
Touch Spot